Lara TMC, Olmedo ZÁ

Language: Spanish
References: 29
Page: 4-17
PDF size: 547.97 Kb.

ABSTRACT

The global increase in the frequency of breast cancer has been more worrisome in developing countries, in which economies like ours where infrastructural, cultural, and communication deficiencies fail to spread information about the severity of this problem and the mechanisms for its early detection and appropriate treatment. The mortality rate figures due to breast cancer in Mexico, in the last 5 years, have been higher than those of cervix cancer, which used to be the first cause of cancer death in women. The implementation of screening national programs with annual mammographies performed on all female population aged forty years or older, has accomplished, in developed countries, an important reduction in breast cancer mortality rate, and has proved to be the first choice to achieve such a decrease. In our national reality, the detection of breast cancer is mostly performed when breast lumps are large enough to be palpated. That is why breast self-examination is the main resource within our reach until generalized screening mammography campaigns that may detect the disease in early, healing stages, and thus lower the high mortality rates of this terrible disease.

REFERENCES

1. Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ. 2005;83(3):171-7.

2. Croswell JM, Ranshoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol. 2010 Jun;37(3):202-15.

3. Zapka J, Taplin SH, Price RA, Cranos C, Yabroff R. Factors in quality care –the case of follow-up to abnormal cancer screening tests–problems in the steps and interfaces of care. J Natl Cancer Inst Monogr. 2010;(40):58-71.

4. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2010 Mar- Apr;60(2):99-119.

5. Anhang Price R, Zapka J, Edwards H, Taplin SH. Organizational factors and the screening process. J Natl Cancer Inst Monogr. 2010;(40):38-57.

6. Sankanarayanan R, Boffetta P. Research on cancer prevention, detection and management in low-and medium-income countries. Ann Oncol. 2010 Oct;21(10):1935-43.

7. Berg WA. Benefits of screening mammography. JAMA. 2010 Jan;13:303(2):169-9.

8. Knaul F, Bustreo F, Ha E, Langer A. Cáncer de mama: ¿por qué integrar la detección temprana con las intervenciones de salud reproductiva en países en vías de desarrollo? Salud Pública Mex (online). 2009;vol. 51 (Suppl 2):s220-s227.

9. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010 Feb; 102(3):170-8.

10. Franco-Marina F, Lazcano-Ponce E, López Carrillo L. Mortalidad por cáncer de mama en México: un análisis de edadperiodo- cohorte. Salud Pública Mex (online). 2009;51 (Suppl 2):s157-s164.

11. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fouth edition-summary document. Ann Oncol. 2008 Apr;19(4):614-22.

12. Hulvat MC, Hansen NM, Jeruss JS. Multidisciplinary care for patients with breast cancer. Surg Clin North Am. 2009 Feb; 89(1):133-76, ix.

13. Hashimoto BE, Morgan GN, Kramer DJ, Lee M. Systematic approach to difficult problems in breast sonography. Ultrasound Q. 2008 Mar;24(1):31-8.

14. Bartella L, Smith CS, Dershaw DD, Liberman L. Imaging breast cancer. Radiol Clin North Am. 2007 Jan;45(1):45-67.

15. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003 Feb 4;138(3):168-75.

16. Berg WA, Blume JD, Cormack JB, Mendelson EB, Leherer D, Böhm-Velez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K; ACRIN 6666 Investigators. JAMA. 2008 May 14;299(18):2151-63.

17. Eklund GW, Busby RC, Miller SH, Job JS. Improved imaging of the augmented breast. AJR Am J Roetgeno. 1988 Sep;151 (3):469-73.

18. O’Flynn EA, Wilson AR, Michel MJ. Image-guided breast biopsy: state of the art. Clin Radiol. 2010 Apr;65(4):259-70.

19. Enriquez L, Listinsky J. Role of MRI in breast cancer management. Cleve Clin J Med. 2009 Sep;76(9):525-32.

20. American College of Radiology (ACR) ACR BI-RADS-mammography. 4th Ed. In ACR Breast imaging reporting and data system, breast imaging Atlas. Reston, Va. 2003.

21. Imbriaco M, Caprio MG, Limite G, Pace L, De Falco T, Capuano E, Salvatore M. Dual-time-point 18F-FDG PET/ CT versus dynamic breast MRI of suspicious breast lesions. AJR Am Roetgenol. 2008 Nov;191(5):1323-30.

22. MacDonald L, Edwards J, Lewellen T, et al. Clinical imaging characteristics of the positron emission mammography camera: PEM Flex Solo II. J Nucl Med. 2009 Oct;50(10):1666-75.

23. US Preventive Services Task Force. Screening for breast cancer:U.S. Preventive Task Force recommendation statement. Ann Intern Med. 2009 Nov;151(10):716-26, W-236.

24. Kopans DB. The recent US preventive services task force guidelines are not supported by the scientific evidence and should be rescinded. J Am Coll Radiol. 2010 Apr;7(4):260-4.

25. Norma Oficial Mexicana NOM-041-SSA2-2002. Para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer de mama. Secretaría de Salud. Diario Oficial de la Federación 17 de septiembre de 2003.

26. Palacio-Mejía LS, Lazcano-Ponce E, Allen-Leigh B, Hernández-Ávila M. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Salud Pública Mex (online). 2009;51 (Suppl 2):s208-s219.

27. Porter P. “Westernizing” women’s risks? Breast cancer in lower-income countries. N Engl J Med. 2008;358(3):213-6